A snapshot of genetic code
Screening entire populations for breast and ovarian cancer gene mutations could prevent millions more cancer cases across the world compared to current clinical practice, according to an international study led by Queen Mary University of London. The research also shows that it is cost effective in high and upper-middle income countries.
The most well-known breast and ovarian cancer causing genes are BRCA1 and BRCA2. These gene mutations cause around 10-20 per cent of ovarian and 6 per cent of breast cancers. If mutation carriers could be identified before they develop disease, most of these cancers could be prevented by drugs, increased screening or surgery.
Current clinical guidelines globally only recommend genetic testing for high-risk women, for example, if they fulfil certain clinical criteria or if there is a strong family history of breast or ovarian cancer. However, over 50 per cent of BRCA carriers do not meet these criteria so are not tested, and over 97 per cent of BRCA carriers in the UK population remain unidentified.
This new study was supported by the NHS Innovation Accelerator Fellowship and women’s cancer charity The Eve Appeal and published in the journal Cancers. The researchers estimated the cost-effectiveness and health impact of BRCA testing in the general population, compared with current standard clinical testing of women designated as high risk, in countries considered high income (UK/USA/Netherlands), upper-middle income (China/Brazil), and low-middle income (India).
The researchers modelled a number of scenarios of population based BRCA-testing and compared the costs and health impact to the current family history based policy. Cost effectiveness was calculated from both a societal and a payer perspective. A payer perspective only includes medical costs incurred by the health system or health providers (such as costs of genetic testing, screening, prevention and cancer treatment). A societal perspective also takes into account costs such as the impact of income lost from inability to work and shorter life spans due to cancer.
The research team found that population based testing was extremely cost effective in high and upper middle income countries from a payer perspective. From a societal perspective it was cost saving in high income countries and cost effective in middle income countries like China and Brazil. Costs of BRCA testing would need to fall to around USD $172 to become cost effective in low income countries like India.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Population based BRCA-testing
- The Role of Second-line Chemotherapy After Gemcitabine Failure in Patients With Advanced Pancreatic Canceron February 28, 2021 at 4:00 pm
Several clinical trials have evaluated the safety and efficacy of second-line chemotherapy after gemcitabine failure in this patient population. Based on the currently available data, there is ...
- Journal of the National Cancer Instituteon February 19, 2021 at 4:00 pm
Genetic Variants and Contralateral Breast Cancer Risk Are the genomic variants known to increase risk of first primary breast cancer also associated with the development of contralateral breast ...
- Differential use of available genetic tests among primary care physicians in the United States: results of a national surveyon February 2, 2021 at 4:00 pm
Methods: Survey of a random sample of 2000 primary care physicians in the United States (n = 1120, 62.3% response rate based on eligible ... clinical outcomes and population health.
- Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testingon January 21, 2021 at 4:02 am
This has resulted in enhanced validation of the predictive capabilities of over 100% 3 than disease risk severity based on age and gender alone ... The initial product focus for the division will be ...
- Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testingon January 20, 2021 at 11:00 pm
This has resulted in enhanced validation of the predictive capabilities of over 100% 3 than disease risk severity based on age and ... the division will be on BRCA testing to align with the ...
Go deeper with Google Headlines on:
Population based BRCA-testing
Go deeper with Bing News on:
Population based testing
- Coronavirus: Test positivity rates drops below 3 percenton March 5, 2021 at 8:16 pm
The Ohio Department of Health reported 1,750 new COVID-19 cases in the last 24 hours in Ohio Friday, leaving the 7-day positivity rate, which includes both confirmed and presumptive cases, at 2.9 perc ...
- New COVID-19 cases continue to stabilize in Forsyth, N.C. Positive test rate is the lowest since Mayon March 5, 2021 at 10:45 am
The key COVID-19 metrics for Forsyth County and statewide continue to stabilize at lower levels, while the county has not had a coronavirus-related deaths for nine consecutive days.
- Saliva-based COVID-19 test to be safe, quick and economical: Studyon March 5, 2021 at 8:09 am
An eight month long study to determine the feasibility of the Saliva-based COVID-19 Rapid Antigen Test (RAT) has revealed that the test is less expensive, faster and safer than the RT-PCR tests which ...
- Study finds Saliva-based Covid-19 test to be safe, quick and economicalon March 5, 2021 at 7:39 am
This study was done to establish the efficacy of the test among the Indian population as not many studies were performed in India on this method of s ...
- Just What the Doctor Ordered? Polygenic Test Gauges Your Alzheimer’s Riskon March 4, 2021 at 3:52 pm
As ever-larger genome-wide association studies make clear, a person’s genetic risk for Alzheimer’s disease is driven by the cumulative effects of myriad variations in their genes. The public will now ...